[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-infarction":676},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,114,0,25,[9,42,74,97,135,166,191,219,268,290,317,344,374,396,422,448,468,487,507,532,558,578,605,629,651],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053901",false,"NCT07696390","The Effect of Virtual Reality Application Diagnosed With Myocardial Infarction","The Effect of Virtual Reality on Vital Signs and Anxiety in Myocardial Infarction Patients Admitted to Cardiology Intensive Care Unit: A Randomized Controlled Study.","Inclusion Criteria:\n\n1. The patient is in intensive care.\n2. The patient has been diagnosed with myocardial infarction.\n3. The patient is between 18 and 70 years old.\n4. The patient is conscious.\n5. The patient is oriented and cooperative.\n6. The patient volunteers to participate in the study.\n7. The patient is open to communication.\n8. The patient agrees to participate in the study.\n9. The patient has no mental, visual, auditory, or speech impairment.\n10. The patient has undergone stent placement.\n11. The patient has STEMI.\n\nExclusion Criteria:\n\n1. The patient has a psychiatric disorder.\n2. The patient has any communication impairment.","ALL","18 Years","70 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study was designed to investigate the effects of VR (virtual reality) glasses on vital signs and anxiety in conscious patients diagnosed with myocardial infarction and admitted to the cardiology intensive care unit.",[27],"Myocardial Infarction",[29],"Myocardial infarction, virtual reality, vital signs, stress","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":31,"type":34},{"date":37,"type":21},"2026-09-18",{"name":39,"class":40},"Yuzuncu Yil University","OTHER",1,{"id":43,"slug":4,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100620809","NCT07362446","Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction","A Randomised, Double-Blind, Placebo-Controlled, Study of Xolatryp in Patients Presenting With STEMI Undergoing Primary PCI","PROTECT-MI","Inclusion Criteria:\n\n* Have provided informed consent.\n* Male patients aged 40 to 75 years of age.- Female patients aged 55 to 75 years of age, or women aged 40 to 55 years that have no possibility of being pregnant.\n* Patient presents with first-time STEMI, scheduled to undergo primary PCI within 6 h of symptom onset and anticipated door to balloon time \\\u003C 2 h.\n* In combination with symptoms consistent with acute MI, patient must demonstrate ST-elevation at the J-point in two contiguous leads.\n* Hemodynamically stable including: systolic BP ≥ 90 mmHg, HR 50-120 bpm.\n* Killip Class I or II.\n* Oxygen saturation ≥ 92% on room air or low-flow oxygen.\n* No ongoing VT\u002FVF at enrolment.\n* Male participants with female partners of child-bearing potential must be ready and able to use highly effective methods of birth control for at least 7 days following IP administration.\n\nExclusion Criteria:\n\n* History or ECG evidence of myocardial infarction or cardiomyopathy.\n* Prior major cardiac surgery, including but not limited to coronary artery bypass graft surgery (CABG).\n* Known contraindication to CMR (e.g. pacemakers, cochlear implants, aneurism clips, claustrophobia, allergy to contrast medium).\n* History of clinically significant renal impairment requiring dialysis or an estimated glomerular filtration rate \\\u003C30 mL\u002Fmin.\n* Estimated or known body weight \\\u003C 50 kg, \\> 120 kg at screening.\n* Concurrent enrolment in another investigational device or drug trial, or less than 30 days or 5 half-lives of investigational device or drug (whichever is longer), since ending another investigational device or drug trial(s) or receiving other investigational treatment(s). Patients who are participating in non-interventional, purely observational trials can be included.\n* Life expectancy of less than 1 year due to non-cardiac pathology in the opinion of the Investigator.\n* Any condition or significant clinical abnormality identified at the time of screening that in the judgment of the Investigator or any sub-Investigator would preclude safe completion of the study.\n* Known history of hypersensitivity to the investigational drug, or excipients, or do not want to be exposed to soy or egg (including products and derivatives).","40 Years","75 Years",{"count":52,"type":21},300,[54],"PHASE2","This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study is to determine whether a medicine called Xolatryp is safe and effective in improving cardiac outcomes. One dose of Xolatryp will be tested in this study.\n\nParticipants are put into two groups randomly, which means by chance. One group receives a single 6-hour continuous intravenous infusion of Xolatryp and one group receives placebo. Participants are in the study for about 30 days.\n\nPlacebo infusion looks like Xolatryp but do not contain any medicine. Participants are followed up via telephone and there is one visit to the study site on day 30.\n\nHeart health is assessed based on the analysis of blood samples, which are collected at the study site, via electrocardiogram (ECG), echocardiogram and cardiac magnetic resonance (CMR) imaging. At the end of the study, the results are compared between the two groups. During the study, the doctors also regularly check the general health of the participants.",[27,57,58,59],"Reperfusion Injury","AMI","STEMI (ST Elevation MI)",[61,62],"STEMI","PCI","2026-06-29",{"date":65,"type":34},"2026-07-01",{"date":67,"type":34},"2026-04-22",{"date":69,"type":21},"2027-09-30",{"name":71,"class":72},"Nyrada Pty Ltd","INDUSTRY",7,{"id":75,"slug":4,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100612382","NCT07252856","Transcultural Digital Solutions in Phase III Cardiac Rehabilitation","CrOss-cultural Model for Postdischarge Assistance and Sustainable Digital Solutions in Phase III Cardiac Rehabilitation: a Randomized Controlled Trial","COMPASS","Inclusion Criteria:\n\n* Age ≥ 18, men and women;\n* patients with atherosclerotic cardiovascular disease (ASCVD) (acute coronary syndrome or chronic coronary syndrome and ischemic heart failure);\n* patients who completed phase II CR and are therefore eligible for CR phase III (maintenance).\n\nExclusion Criteria:\n\n* Unable to sign the informed consent;\n* unable or unwilling to use digital devices due to mental\u002Fcognitive issues or without a support person helping them to access the respective technical devices;\n* pregnant, lactating or women planning pregnancy during the course of the trial.",{"count":82,"type":21},306,[24],"Multicenter Prospective Controlled Randomized Trial, open-label, in patients with atherosclerotic cardiovascular disease (ASCVD) (acute coronary syndrome or chronic coronary syndrome and ischemic heart failure) and an approved indication for cardiac rehabilitation (CR). Patients completing phase II CR will be randomized 1:1 to usual Phase-III care (standard care) versus standard care plus the Digitally-Enhanced Extended PrEvention \\& Rehabilitation (DEEPER) package (intervention). Primary outcome is 6-month change in composite Life's Crucial 9 (LC9) (LE8 + PHQ-9).",[86,27],"Heart Failure","2026-06-26",{"date":89,"type":34},"2026-06-30",{"date":91,"type":34},"2026-04-20",{"date":93,"type":21},"2027-07-31",{"name":95,"class":40},"Fondazione Don Carlo Gnocchi Onlus",6,{"id":98,"slug":4,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100394478","NCT04416581","Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy","A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease","PROTECT-HBR","Inclusion Criteria:\n\n1. Patients 19 years of age or older with known cardiac and vascular disease who are receiving chronic use of antithrombotic drugs (either antiplatelets, oral anticoagulant (OAC), and its combinations). Specific clinical conditions that may confer a need for long-term antithrombotic therapy may include documented coronary artery disease (stable or unstable angina, acute coronary syndrome, a history of myocardial infarction, or any coronary revascularization), documented cerebrovascular disease (stroke or transient ischemic attack), known peripheral arterial disease or a history of peripheral arterial revascularization, atrial fibrillation, or valvular heart disease requiring interventions (transcatheter aortic valve replacement or transcatheter mitral-valve repair). Concomitant use of a proton pump inhibitor is strongly recommended in patients receiving aspirin monotherapy, DAPT (dual antiplatelet therapy; aspirin plus any P2Y12 inhibitors), DAT (dual antithrombotic therapy; antiplatelet drug plus OAC), TAT (triple antithrombotic therapy; DAPT plus OAC), or OAC monotherapy (warfarin or direct oral anticoagulants) who are at high risk of GI bleeding in order to reduce the risk of gastric bleed or GI events. Based on clinical guidelines, the use of P2Y12 inhibitor monotherapy (i.e. clopidogrel, ticagrelor, or prasugrel) is not considered in trial enrollment.\n2. On the basis of clinical guidelines and expert consensus documents, we defined a study population with an increased risk of gastrointestinal bleeding if they had a least 1 or more criteria of the following characteristics. Eligible patients for randomization must meet at least 1 characteristic of these criteria:\n\n   \\*Definition of patients who are at high risk of gastrointestinal bleeding\n   1. Age ≥65 years\n   2. Concomitant use of OAC and any antiplatelet therapy (mono or DAPT) (i.e., DAT or TAT)\n   3. Long-term use of oral NSAIDs (non-steroidal anti-inflammatory drugs) or steroids or high-dose NSAID therapy even during a relatively short-term period.\n   4. History of prior GI bleeding events at any time\n   5. History of a previously complicated ulcer\n   6. History of peptic ulcer disease or a previously uncomplicated ulcer\n   7. Documented Helicobacter pylori infection\n3. Patients who voluntarily participated in the written agreement\n\nExclusion Criteria:\n\n1. Active bleeding at the time of inclusion or a history of hereditary or acquired hemostatic disorder\n2. Any clinical contraindication to using of antithrombotic therapies (antiplatelet agents or OAC)\n3. Concurrent use of PPI or P-CAB within 4 weeks before randomization\n4. Hemodynamically unstable conditions at the time of inclusion: cardiogenic shock at the time of randomization, refractory ventricular arrhythmias, or congestive heart failure (New York Heart Association class IV).\n5. Baseline severe anemia (Hgb \\\u003C8 g\u002Fdl at baseline) or transfusion within 4 weeks before randomization\n6. Baseline severe thrombocytopenia (platelet count \\\u003C50,000\u002Fmm3)\n7. Renal failure dependent on dialysis or severe renal insufficiency (creatinine clearance \\\u003C15 ml\u002Fmin)\n8. Severe chronic liver disease (defined as variceal haemorrhage, ascites, hepatic encephalopathy, or jaundice)\n9. Hypersensitivity or contraindication to PPI, P-CAB, any of the product components, or substituted benzimidazoles\n10. Use of clarithromycin and hypersensitivity to macrolide antibiotics for Helicobacter pylori eradication\n11. Concomitant use of clarithromycin with terfenadine, cisapride, astemizole, or pimozide for Helicobacter pylori eradication\n12. Systemic treatment with strong CYP 3A4 and p-glycoprotein (P-GP) inhibitors (e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus \\[HIV\\]-protease inhibitors, such as ritonavir)\n13. Patients who take atazanavir, nelfinavir, or rilpivirine-containing products (see Drug-Drug interaction section)\n14. Clinically significant laboratory abnormality at screening (estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin or elevated liver enzyme \\[AST, ALT, ALP, total bilirubin\\] \\> 3 times upper normal limit \\[UNL\\] or any other condition that, in the opinion of the Investigator, precludes participation in the study\n15. Any known or suspected malignancy\n16. Patients with non-cardiac co-morbidities with a life expectancy of less than 12 months\n17. Patients with active treatment for H-pylori infection\n18. Women who are pregnant or breastfeeding or female subjects, premenopausal who are not surgically sterile, or, if sexually active not practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, who have a positive pregnancy test at screening\n19. Participation in another clinical study within 12 months. However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;\n\n    1. Participated in the observational study expected no effect on the safety and\u002For effectiveness evaluation of this trial\n    2. Screening failed before any interventional factor is involved\n    3. Participated in academic trials like strategic or medical device comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies","19 Years",{"count":106,"type":21},3320,[108],"PHASE4","The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known cardiac and vascular disease receiving chronic use of antithrombotic drugs (either antiplatelets, OAC, and its combinations) who are at high GI bleeding risk. The primary hypothesis is that P-CAB (experimental arm) would non-inferior to PPI (standard arm) with respect to the rate of the primary composite end point of GI events at 12 months after randomization.",[111,112,113,27],"Coronary Artery Disease","Percutaneous Coronary Intervention","Acute Coronary Syndrome",[115,116,117,118,119,120,121,122,123,124,125],"gastroduodenal ulcer","gastrointestinal hemorrhage","peptic ulcer","acute coronary syndrome","coronary artery stent placement","antiplatelet","anticoagulant therapy","PPI","P-CAB","Proton-pump inhibitors","Potassium-Competitive Acid Blockers","2026-06-24",{"date":87,"type":34},{"date":129,"type":34},"2021-05-12",{"date":131,"type":21},"2028-02-28",{"name":133,"class":40},"Duk-Woo Park, MD",45,{"id":136,"slug":4,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":143,"studyType":144,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":41},"100636249","NCT07563231","Polymer-free Sirolimus Eluting Stent: Real-world Investigation of Safety and Outcomes","POLARIS : POLymer-free Sirolimus Eluting Stent: Real-world Investigation of Safety and Outcomes","POLARIS","Inclusion Criteria:\n\n* Age \\>= 18 years at the time of the index procedure.\n* Percutaneous coronary intervention performed at Geneva University Hospitals between January 2021 and December 2025.\n* Implantation of at least one study device\n* Indication for PCI according to current European or American guidelines.\n* Able and willing to provide written informed consent.\n* Sufficient knowledge of French, German, English, or Italian to understand the patient information document.\n\nExclusion Criteria:\n\n* Documented refusal to participate in research through opt-out from general consent.\n* Inability to provide informed consent (cognitive impairment or other).\n* Inability to be contacted for informed consent (no valid contact information, or unreachable after three contact attempts).\n* Life expectancy less than 12 months due to non-cardiac comorbidities at the time of consent.\n* Participation in another clinical trial that would interfere with the endpoints of this registry.",{"count":52,"type":21},"5 Years","OBSERVATIONAL","POLARIS is a prospective, single-centre, single-arm observational pilot registry evaluating the real-world safety and efficacy of the Focus np (Abluminus np, Concept Medical, Tampa, FL, USA) polymer-free sirolimus-eluting stent in consecutive adult patients undergoing percutaneous coronary intervention (PCI). The primary endpoint is target lesion failure (TLF) at 12 months, defined per Academic Research Consortium-2 (ARC-2) criteria as the device-oriented composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularisation. Patients treated since January 2021 will be retrospectively identified and prospectively consented, with follow-up through 5 years. The registry will provide the first Western clinical evidence on this CE-marked device and serve as a template for a future national Swiss multicentre registry.",[111,113,27,147,112],"Stent Thrombosis",[149,150,151,152,153,154,155],"drug-eluting stent","polymer-free stent","sirolimus","percutaneous coronary intervention","target lesion failure","registry","real-world evidence","NOT_YET_RECRUITING","2026-06-05",{"date":159,"type":34},"2026-06-09",{"date":161,"type":21},"2026-06",{"date":163,"type":21},"2036-06",{"name":165,"class":40},"Dorian Garin",{"id":167,"slug":4,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":190},"100643011","NCT07636642","Sixth Generation High-sensitivity Cardiac Troponin T for the Early Rule Out of Myocardial Infarction: a Controlled Before and After Study","STEREO-MI","Inclusion Criteria:\n\n* Age 18 years and over.\n* Attending clinician suspects acute coronary syndrome.\n* At least one measurement of cardiac troponin using the Gen 5 or Gen 6 hs-cTnT assay.\n\nExclusion Criteria:\n\n* Insufficient clinical information to perform record linkage.\n* Not resident in Scotland.\n* Previous enrolment in the study.",{"count":173,"type":21},19500,[24],"Cardiac troponin is a protein released into the blood when the heart muscle is damaged. Measuring this protein helps doctors diagnose a heart attack (also called a myocardial infarction). Modern blood tests, known as high-sensitivity cardiac troponin assays, can detect very small amounts of this protein.\n\nA new version of this test, called Troponin T high-sensitivity Gen 6, has recently been developed and approved for use. It is designed to be more accurate and reliable, detecting smaller changes in troponin levels and being less affected by technical interference. The investigators believe this improved test will allow doctors to diagnose heart attacks more quickly and decide sooner who needs to stay in hospital and who can safely go home. This could help reduce overcrowding in Accident and Emergency (A\\&E) departments, a major challenge for the NHS.\n\nThis study will examine whether switching to this new test across a health board shortens the time patients with suspected heart attacks spend in the Emergency Department. The investigators will use information from the DataLoch Heart Disease Registry, which automatically collects anonymised hospital data for patients attending with possible heart attacks. The investigators will compare data from one year before and one year after implementation to see whether average length of stay changes and to confirm that patient safety remains high. This investigators will also measure both the current and new versions of the troponin test in surplus blood samples collected during two six-month periods-one before and one after the new test is introduced. This will allows the investigators to directly compare the two tests reliably.\n\nPatients will not need to do anything extra to take part - the study uses information and samples already collected as part of their usual care.",[27],[178,179,118,180,181],"cardiac troponin","myocardial infarction","accelerated decision pathway","Troponin T high sensitivity generation six","2026-06-04",{"date":159,"type":34},{"date":185,"type":21},"2026-06-01",{"date":187,"type":21},"2029-05",{"name":189,"class":40},"University of Edinburgh",3,{"id":192,"slug":4,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":217,"locationsCount":41},"100634540","NCT07541014","TeleheartCR vs. Clinic-Based Cardiac Rehabilitation After Acute Coronary Syndrome","Comparing a Novel Telehealth-enabled Hybrid Cardiac Rehabilitation Program to Clinic-based Cardiac Rehabilitation for Improving Patient Engagement and Functional Outcomes After ACS","Inclusion Criteria:\n\n* Age 18 years or older\n* Diagnosis of acute coronary syndrome within the past 12 months\n* Eligible for outpatient cardiac rehabilitation\n* Able to read and speak English or Spanish\n* Resides in New York State\n\nExclusion Criteria:\n\n* Severe medical or psychiatric comorbidities that would prevent safe or adequate participation\n* High risk for adverse exercise-related cardiovascular events\n* Initiation of cardiac rehabilitation prior to enrollment (i.e., \\>1 session completed)\n* Conditions that would interfere with safe or consistent participation in study procedures\n* Home environment or willingness not compatible with safe or adequate participation\n* Not expected to be available for follow-up during the study period\n* Current participation in another interventional clinical trial that may affect study outcomes",{"count":198,"type":21},250,[24],"Cardiac rehabilitation (CR) is an effective evidence-based intervention that improves outcomes in patients with acute coronary syndrome (ACS), but many eligible patients do not complete the program. A hybrid CR intervention that combines telehealth, home-based, and clinic-based components (TeleheartCR) may increase participation by addressing barriers to access while maintaining the functional capacity benefits of traditional CR. The purpose of this study is to conduct a randomized controlled trial comparing TeleheartCR with traditional clinic-based CR in patients with ACS to evaluate differences in program adherence and pre-to-post program change in functional capacity.",[202,27],"Acute Coronary Syndrome (ACS)",[204,205,206,207,208,209,210],"Cardiac Rehabilitation","Hybrid Cardiac Rehabilitation","Virtual Cardiac Rehabilitation","Implementation Science","Adherence","Functional Capacity","Telehealth","2026-05-30",{"date":213,"type":34},"2026-06-03",{"date":215,"type":34},"2026-05-19",{"date":187,"type":21},{"name":218,"class":40},"Columbia University",{"id":220,"slug":4,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":226,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":229,"conditions":230,"keywords":244,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100569808","NCT06699056","AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor","AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Using COR ECG Wearable Monitor","EFACT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able and eligible to wear a Holter monitor\n\nExclusion Criteria:\n\n* Receiving mechanical respiratory or circulatory support, or renal support therapy, at the time of screening or during Visit #1\n* Any condition that, in the investigator's opinion, could interfere with compliance with the study protocol or pose a safety risk to the participant\n* History of poor tolerance or severe skin reactions to ECG adhesive materials",true,{"count":228,"type":21},2000,"This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the American Society of Echocardiography's (ASE) 4-category scale. The software analyzes continuous ECG waveform data acquired by the FDA-cleared Peerbridge COR® ECG Wearable Monitor, an ambulatory patch device designed for use during daily activities. The AI software assists clinicians in cardiac evaluations by estimating EF severity, which reflects how well the heart pumps blood.\n\nIn this study, EF severity determination will be made using 5-minute ECG recordings collected during a 15-minute resting period with participants seated upright. The results will be compared to EF severity obtained from an FDA-cleared, non-contrast transthoracic echocardiogram (TTE) predicate device. This comparison aims to validate the accuracy of the AI software.",[231,232,233,234,235,86,236,237,238,27,239,240,241,242,243],"Ventricular Ejection Fraction","LVF","LV Dysfunction","Atrial Enlargement","Conduction Defect","Valvular Heart Disease","Ischemic Heart Disease","Cardiotoxicity","Dilated Cardiomyopathy","HFrEF - Heart Failure With Reduced Ejection Fraction","HFpEF - Heart Failure With Preserved Ejection Fraction","Syncope","Remodeling, Cardiac",[245,246,247,248,249,250,251,233,252,253,254,255,256,257,234,258],"ECG Patch","LVEF","Holter","ECG Wearable","COR","Atrial Conduction","ECG Biomarker","SaMD","Clinical Decision Support","ECG","EF Severity","Ejection Fraction","AI","Electrical Remodeling","2026-05-28",{"date":185,"type":34},{"date":262,"type":34},"2024-11-21",{"date":264,"type":21},"2027-11-15",{"name":266,"class":72},"Peerbridge Health, Inc",8,{"id":269,"slug":4,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":286,"leadSponsor":288,"locationsCount":41},"100637765","NCT07620119","Machine Learning for Diagnosis of Occlusive MI in LBBB Patients","Development of a Machine Learning Model for the Diagnosis of Occlusive Myocardial Infarction in the Setting of Left Bundle Branch Block","AI-LBBB","Inclusion Criteria:\n\n* Patients aged 18 years and older who present to the emergency department. Patients presenting with acute ischemic chest pain or clinical ischemia-equivalent symptoms (such as acute dyspnea, unexplained diaphoresis, or syncope).\n\nPatients with a confirmed Left Bundle Branch Block (LBBB) on their initial 12-lead electrocardiogram (ECG), which can be either newly developed or known\u002Fchronic.\n\nPatients who undergo invasive coronary angiography during their index hospital admission.\n\nPatients or their legally authorized representatives who provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients under the age of 18. Pregnant or lactating women. Patients with poor-quality or uninterpretable digital ECG recordings due to severe artifact, missing leads, or technical errors.\n\nPatients who develop cardiopulmonary arrest before an initial diagnostic 12-lead ECG can be obtained in the emergency department.\n\nPatients transferred from another healthcare facility who have already undergone coronary angiography or revascularization.\n\nPatients who decline to participate or refuse to provide written informed consent.",{"count":20,"type":21},"This study investigates a new way to diagnose severe heart attacks in patients who have a specific electrical heart pattern called a Left Bundle Branch Block (LBBB). When patients present to the emergency department with chest pain, doctors routinely perform an electrocardiogram (ECG) to check for a heart attack. However, the presence of an LBBB can alter the heart's electrical signals on the ECG, effectively masking or hiding the typical signs of an ongoing acute coronary occlusion (a completely blocked artery). This making it highly challenging for emergency physicians to make an accurate and rapid diagnosis.\n\nThe primary purpose of this prospective and observational research is to develop and evaluate an artificial intelligence\u002Fmachine learning (ML) model that can analyze digital 12-lead ECG signals to accurately predict a true blocked coronary artery in patients with LBBB. The machine learning model will analyze raw digital ECG waveforms to detect subtle, microscopic patterns that might be missed by the human eye.\n\nTo confirm the accuracy of the model, its predictions will be compared directly with invasive coronary angiography results, which is the gold standard reference method used to visualize blocked vessels. Additionally, the study aims to evaluate if the model can differentiate between a true heart attack caused by a blocked artery (Type 1 MI) and other non-occlusive conditions that cause elevated heart enzymes (Type 2 MI). Ultimately, the investigators intend to determine whether integrating this machine learning tool into emergency care can safely reduce the rate of unnecessary emergency invasive procedures for patients who do not have a true coronary blockage.",[278,279,280,281,27],"Acute Myocardial Infarction (AMI)","Left Bundle Branch Block","Coronary Occlusion\u002FThrombosis","Chest Pain","2026-05-22",{"date":284,"type":34},"2026-06-02",{"date":185,"type":21},{"date":287,"type":21},"2027-01-31",{"name":289,"class":40},"Konya City Hospital",{"id":291,"slug":4,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":298,"conditions":299,"keywords":305,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":41},"100640061","NCT07617376","Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions","Inclusion Criteria:\n\n* Acute cardiac hospitalization,\n* Planned discharge home within the next 48 hours following completion of in-hospital treatment,\n* No prior influenza vaccination for the current influenza season.\n\nExclusion Criteria:\n\n* History of a severe adverse reaction to influenza vaccination,\n* Allergy to any component of the vaccine to be administered,\n* Discharge to another hospital for continuation of treatment or discharge to a long-term care facility,\n* Antibiotic therapy to be continued after discharge.",{"count":296,"type":21},400,[108],"Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge.\n\nIn this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.",[27,300,301,302,303,304],"Decompensated Chronic Heart Failure","Acute Heart Failure (AHF)","Pulmonary Embolism Acute","Hypertension Emergency","Arrhythmias",[306,307,308],"influenza vaccination","acute cardiac emergencies","pre-discharg vaccination","2026-05-20",{"date":185,"type":34},{"date":312,"type":34},"2025-11-12",{"date":314,"type":21},"2027-07-01",{"name":316,"class":40},"Wroclaw Medical University",{"id":318,"slug":4,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":343},"100500266","NCT05794022","Cohort of STEMI Patients 2","CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction","HIBISCUS STEMI","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG.\n* Management in primary ACT\n* Prior oral informed consent followed by signed informed consent as soon as possible.\n\nExclusion Criteria:\n\n* Diagnosis of STEMI not confirmed on angiography\n* Inability to give the subject informed information\n* Lack of coverage by a social security scheme\n* Obvious contraindication to injected magnetic resonance imaging (claustrophobia, pacemaker, defibrillator, or a metallic body (ferromagnetic), severe renal insufficiency (GFR\\\u003C30 ml\u002Fmin), known allergy to the contrast medium ....)\n* Pregnant woman or woman of childbearing age without effective contraception, breastfeeding woman.\n* Deprivation of civil rights (curators, guardianship, safeguard of justice)",{"count":52,"type":21},[24],"ST-segment elevation myocardial infarction (STEMI) is an acute condition that accounts for 75% of sudden deaths in adults over 35 years of age and more than half of all cases of chronic heart failure. However, the mechanism of myocardial infarction remains poorly understood. At present, there is no national information system for myocardial infarction, as there is for other diseases such as multiple sclerosis (OFSEP cohort).\n\nThe purpose of this cohort is to enable studies and research projects to be carried out on the descriptive epidemiology of myocardial infarction, monitoring of patients undergoing treatment (safety, efficacy), quality of life and functional consequences of infarction, and research into new biological and imaging prognostic biomarkers. Its general objective is to provide researchers, hospital practitioners, medical interns, academics or industrialists with a quality epidemiological tool for research.",[27],[329,330,331,332,61,333],"Myocardial infarction","bio-collection","Imaging markers","biomarkers","clinical outcomes","2026-05-13",{"date":336,"type":34},"2026-05-14",{"date":338,"type":34},"2023-05-03",{"date":340,"type":21},"2033-06-03",{"name":342,"class":40},"Hospices Civils de Lyon",2,{"id":345,"slug":4,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":16,"minAge":104,"maxAge":4,"enrollmentInfo":351,"targetDuration":353,"studyType":144,"phases":4,"briefSummary":354,"conditions":355,"keywords":358,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":41},"100460207","NCT05272618","Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries","Clinical Relevance of Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries","CMD-MINOCA","Inclusion Criteria:\n\n* Subject with age ≥19 years and acute myocardial infarction\n\n  * Rise and\u002For fall of cardiac troponin with one level \\>99 percentile plus ischemic signs\u002Fsymptoms\n\n    * Subject with non-obstructive coronary arteries\n  * \\\u003C50% diameter stenosis or\n  * fractional flow reserve (FFR) \\>0.80 ③ Subject without previous history of coronary artery disease\n\n    * Subject who performed invasive coronary angiography within 24 hours after presentation ⑤ Subject who eligible for invasive and non-invasive coronary physiologic assessment\n\nExclusion Criteria:\n\n* Subject with obstructive coronary arteries\n\n  * Subject with alternate diagnosis including sepsis, pulmonary embolism, myocarditis, Takotsubo syndrome, spontaneous coronary dissection, and other cardiomyopathies.\n\n    * Subject with cardiogenic shock or cardiac arrest ④ Subject who has non-cardiac co-morbid conditions with life expectancy \\\u003C1 year ⑤ Subject or lactating women ⑥ Subject unable to provide consent",{"count":352,"type":21},150,"12 Months","To compare clinical outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA) according to the coronary microvascular dysfunction (CMD), evaluated by optical coherence tomography (OCT), invasive and non-invasive coronary physiologic assessment.",[27,356,357],"Coronary Microvascular Dysfunction","Vasospasm, Coronary",[359,360,361,362,363,364],"MINOCA","Coronary physiology","Cardiac PET","CFR","IMR","OCT","2026-05-08",{"date":367,"type":34},"2026-05-12",{"date":369,"type":34},"2022-02-14",{"date":371,"type":21},"2030-12-31",{"name":373,"class":40},"Chonnam National University Hospital",{"id":375,"slug":4,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":382,"conditions":383,"keywords":384,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":393,"locationsCount":395},"100603880","NCT07142265","Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients","STREAMLINE","Inclusion Criteria:\n\n* Adult patients of both genders\n* Myocardial Infarction diagnosis\n* Dyslipidemia diagnosis\n* The first injection of inclisiran no later than 14 ± 5 days after the STEMI\u002Fnon-STEMI\n* LDL-C \\> 5 mmol\u002FL (statin-naive patients) or LDL-C \\> 2.5 mmol\u002FL (on the basis of statin MTD) at the time of hospitalization or no target LDL-C level (\\> 1.4 mmol\u002FL or no LDL-C level decrease by 50% on statin MTD + ezetimibe)\n* Signed Informed Consent Form (ICF)\n\nExclusion Criteria:\n\n* Severe oncological and somatic diseases with system and organ failure\\*\n* Competing diseases that caused emergency hospitalization (pulmonary thromboembolism, aortic dissection)\n* History of therapy with PCSK9 inhibitors\n* Active inflammatory liver disease or the levels of AST, ALT \\> 3 times, or total bilirubin \\> 2 times higher than the upper limit of norm\n* Any other MACE in the anamnesis","100 Years",{"count":52,"type":21},"Evaluation of clinical outcomes during 12 months after inclisiran initiation in patients after STEMI\u002Fnon-STEMI in real-world settings in Russia. It is also planned to study the therapy effect on the lipid profile characteristics, its safety, the state of atherosclerotic plaques according to carotid ultrasound, the frequency of hospitalizations and the need for intensive follow-up.",[27],[329,385,386],"NIS","inclisiran","2026-05-06",{"date":389,"type":34},"2026-05-11",{"date":391,"type":34},"2025-09-30",{"date":69,"type":21},{"name":394,"class":72},"Novartis Pharmaceuticals",16,{"id":397,"slug":4,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":402,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":405,"conditions":406,"keywords":409,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":41},"100414125","NCT04672551","EMDR Treatment in PTSD Following Cardiac Events","EMDR_PTSD_MI","Inclusion Criteria:\n\n* Age between 18-70 years\n* Men or women\n* STEMI (irrespective of troponin, but ST-elevation) or non-STEMI (troponin positive) at the time of the cardiac event, as verified by the cardiologist\n* Diagnosis of PTSD caused by the cardiac event\n\nExclusion Criteria:\n\n* Psychotic disorder, bipolar disorder, substance abuse as measured with the Mini International Neuropsychiatric Interview (M.I.N.I)\n* Acute suicidal ideation as assessed with the M.I.N.I.\n* Non-selective beta blockers (e.g., propranolol) during the study period\n* Ongoing psychological\u002Fpsychiatric treatment outside of the trial during the study period\n* Visionary problems, e.g. strabismus, which does not allow adequate eye movements\n* Insufficient knowledge of the German language\n* Expected inability or willingness to follow the study protocol\n* Regular medication with benzodiazepine",{"count":403,"type":21},60,[24],"Cardiac events can often result in debilitating and persistent psychological symptoms. A key question involves whether optimal treatment of cardiac-induced posttraumatic stress disorder (PTSD) reduces PTSD symptoms and thereby may offset the risk of recurrent or worsening cardiovascular disease. Cardiac-induced PTSD 1) is prevalent, 2) features symptoms unique to internal ongoing somatic threat, with fears and worries that can be distinguished from PTSD resulting from external causes, 3) is persistent, 4) is associated with negative physical and emotional consequences, and 5) has not been the subject of randomized-controlled treatment trials (RCT). There is preliminary evidence suggesting that patients with cardiac-disease induced PTSD might particularly profit from EMDR. Nevertheless, this possibility has not been tested in cardiac-induced PTSD. Currently, patients with cardiac-induced PTSD are not routinely offered trauma-focused therapies, with a lack of scientific evidence likely being one major reason for this omission. If our proposed RCT shows that EMDR can be an effective treatment for patients with ACS-induced PTSD, EMDR could be routinely implemented as first-line treatment. The RCT outcomes might inform larger trials to test whether poor prognosis in terms of major adverse cardiovascular events can be improved through EMDR in patients with cardiac-induced PTSD.",[407,27,408],"Posttraumatic Stress Disorder","Eye Movement Desensitization and Reprocessing",[410,411,412,413],"PTSD","MI","ACS","EMDR",{"date":415,"type":34},"2026-05-07",{"date":417,"type":34},"2020-11-21",{"date":419,"type":21},"2027-11-30",{"name":421,"class":40},"University of Zurich",{"id":423,"slug":4,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":16,"minAge":104,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":22,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":447},"100533587","NCT06227754","OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts","Randomized Controlled Trial of Optical Coherence Tomography Versus Angiography for Culprit Lesion Revascularization in Patients With Acute Myocardial Infarction","FRAME-AMI3","Inclusion Criteria:\n\n* Subject must be at least 19 years of age\n* Acute ST-segment elevation myocardial infarction (STEMI)\n\n  \\*STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1\n* Primary percutaneous coronary intervention (PCI) in \\\u003C 12 h after the onset of symptoms for STEMI patients\n* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Target lesions not amenable for PCI by operators' decision\n* Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's discretion)\n* Creatinine clearance ≤30 ml\u002Fmin\u002F1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance)\n* Cardiogenic shock (Killip class IV) at presentation\n* Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus\n* Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)\n* Pregnancy or breast feeding\n* Non-cardiac co-morbid conditions are present with life expectancy \\\u003C2 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n* Unwillingness or inability to comply with the procedures described in this protocol",{"count":430,"type":21},1500,[24],"The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).",[434,27],"ST Elevation Myocardial Infarction",[436,437,438,439],"ST-segment elevation MI","Optical coherence tomography","Intravascular imaging","Primary PCI","2026-05-05",{"date":365,"type":34},{"date":443,"type":34},"2024-03-25",{"date":445,"type":21},"2031-12-31",{"name":373,"class":40},18,{"id":449,"slug":4,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":41},"100402548","NCT04521699","Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.","Examination of the Impact of CalmiGo's Stress Management Device on Vascular Health and Cardiovascular Disease Risk , and Markers of Mental Stress in Patients Following a Myocardial Infarction Participating in Clinically Indicated Cardiac Rehabilitation","CalmiGo","Inclusion Criteria:\n\n* 18 years of age or older\n* Ability to use the CamliGo device for 12-weeks\n* Willingness to complete study questionnaires, blood tests,\\& EndoPat testing at the beginning and end of study\n* Patients who have had a recent MI who will be undergoing clinically indicated Cardiac Rehabilitation\n* Patients who have had a coronary or structural intervention performed in the cardiac catheterization laboratory within the last month, including: coronary stenting; coronary balloon angioplasty; transcatheter aortic valve replacement; mitral valve interventions; patent foramen ovale closures; alcohol septal ablation; paravalvular leak closure.\n* Patients being seen in the Chest Pain Clinic for Atypical chest pain\n\nExclusion Criteria:\n\n* Cognitively impaired patients\n* Patient with Bipolar disorder, psychosis or delusional disorder\n* History of substance abuse or dependence\n* History of suicidality\n* Unstable cardiovascular or pulmonary disease\n* History of seizures\n* Latex allergy",{"count":456,"type":21},100,[24],"The primary purpose of this study is to determine if there are significant differences with respect to baseline between those randomized to CGo and standard-of-care versus standard-of-care alone after completing 12-weeks of therapy in terms of peripheral endothelial function measured by EndoPAT.",[27],"2026-04-29",{"date":440,"type":34},{"date":463,"type":34},"2022-01-13",{"date":465,"type":21},"2026-12",{"name":467,"class":40},"Mayo Clinic",{"id":469,"slug":4,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":226,"sex":16,"minAge":475,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":485,"locationsCount":343},"100397727","NCT04458883","The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field","The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field The TITAN Study","TITAN","Inclusion Criteria:\n\n* Participant who is willing and able to give informed consent for participation in the study\n* Healthy volunteers willing to give informed consent for participation in the study\n* Patients diagnosed with a previous myocardial infarction\n\nExclusion Criteria:\n\n* Unwillingness to participate\n* Claustrophobia\n* Contraindication to MRI scanning such as implantable cardiac devices\n* Participants who have had a previous myocardial infarction in the past of which they may not be aware and this is discovered whilst being scanned on the 3T MRI scanner, or who may have any other cardiology condition that they were previously unaware will not be included in the healthy control group, even if they present themselves to us as \"healthy\" at the time of the study visit\n* Pregnancy\n* Body habitus that may preclude comfortable positioning of the volunteer in either of the MRI scanners (\\>50cm in diameter)\n* Participants with abnormal kidney function that will preclude them from receiving a contrast agent","20 Years",{"count":352,"type":21},[24],"The main aim of the study is to build and test a cardiac-specific coil purposely assembled in house to suit the FFC-MRI whole-body prototype and to test if it could be used for clinical cardiac scans in human subject populations.",[27],{"date":481,"type":34},"2026-04-30",{"date":483,"type":34},"2020-08-01",{"date":93,"type":21},{"name":486,"class":40},"University of Aberdeen",{"id":488,"slug":4,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":22,"phases":496,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":504,"locationsCount":506},"100509991","NCT05920629","Moderate Alcohol Consumption and Heart Function in Patients With a Recent Myocardial Infarction","Moderate Alcohol Consumption and Heart Function in Patients With a Recent Myocardial Infarction: a Multicentre Randomized Controlled Trial","Moderate","Inclusion Criteria:\n\n* Hospitalization for acute ST-elevation MI (STEMI) or non ST-elevation MI (NSTEMI) within 365 days prior to screening\n* Men and women aged ≥18 years who are capable and willing to provide consent\n* ECG ischemic changes, such as persistent or dynamic ST-segment deviation\n* Evidence of positive high-sensitive troponin\n* Confirmation of coronary heart disease aetiology by angiography\n* Capacity to complete study visits with strict adherence to the protocol assignment\n* Self-reported average alcohol consumption of between 1 and 28 standard units per week in the 12 months prior to the index hospitalization.\n\nExclusion Criteria:\n\n* High alcohol consumption, defined as an average of \\>28 alcoholic standard units\u002Fweek in the 12 months prior to the index hospitalization\n* Alcohol use disorder (AUDIT score \\>20 at screening)\n* History of alcohol or substance abuse\n* Naïve to alcohol consumption\n* Light alcohol consumption (\\\u003C1 standard units by week)\n* Prior severe heart failure (NYHA III-IV)\n* Severe LV dysfunction at screening (\\\u003C30%)\n* History of gastric ulcer or gastro-intestinal bleeding\n* Serious chronic liver disease or liver test elevation (\\> 3 times upper limit normal range)\n* Personal history of any colon or liver cancer\n* Any active malignancy (less than 5 years or ongoing treatment)\n* Estimated glomerular filtration rate 15 ml\u002Fmin\u002F1.73m² or end-stage renal disease\n* Any medication (investigator's discretion) making study participation impractical or precluding required follow-up\n* History of organ transplant\n* Participation in another trial testing intervention on similar CV outcomes (investigator's discretion)\n* Any medical, geographic, or social factor making study participation impractical or precluding required follow-up.\n* Pregnant, breastfeeding or planning to become pregnant within 12 months.",{"count":495,"type":21},220,[24],"A total of 220 patients (110 per arm) who report moderate alcohol consumption between 1 and 28 standard units (1 standard unit = \\~10 grams) per week in the 12 months prior to hospital admission will be planned for randomization, using a 1:1 ratio to pursue moderate alcohol consumption (1 standard unit per day for women and 2 standard units per day for men) or abstinence (except for one drink on predefined\u002Fagreed special occasions) for a total duration of 3 months. An echocardiography will be performed at baseline and 3 months to assess changes in systolic cardiac function (LVEF) for the primary endpoint. A core laboratory team blinded to assignment will perform data interpretation.",[27],{"date":500,"type":34},"2026-04-28",{"date":502,"type":34},"2023-06-01",{"date":481,"type":21},{"name":505,"class":40},"Baris Gencer",4,{"id":508,"slug":4,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":22,"phases":517,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":41},"100635176","NCT07549282","Use Dexmedetomidine To Protect Myocardial Injury Evaluation","Effects of Preoperative Intranasal Dexmedetomidine on Perioperative Myocardial Injury and Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: A Prospective, Randomized Controlled Trial","UDOPIE","Inclusion Criteria:\n\n* 18 years ≤ age ≤ 85 years;\n* Patients scheduled to undergo elective coronary angiography or percutaneous coronary intervention (PCI);\n* Classified as American Society of Anesthesiologists (ASA) physical status I-III (ranging from patients with mild systemic disease to those with more severe systemic disease that limits normal physical activity but who remain able to perform light daily tasks);\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Allergy or contraindication to dexmedetomidine, such as severe bradycardia (resting heart rate \\\u003C50 beats\u002Fmin), sick sinus syndrome, second-degree or higher atrioventricular block without a pacemaker;\n* Severe cardiac dysfunction (left ventricular ejection fraction \\\u003C35% or New York Heart Association functional class III-IV), cardiogenic shock, or hemodynamically unstable patients;\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg) or hypotension (systolic blood pressure \\\u003C90 mmHg);\n* Sleep apnea-hypopnea syndrome or Body Mass Index \\>30 kg\u002Fm²;\n* Use of alpha-2 adrenergic receptor agonists (e.g., clonidine) or antagonists, or tricyclic antidepressants, which may affect the action of the study drug, within 1 month before the procedure;\n* Language, visual, or hearing impairment that may affect cognitive assessment;\n* Hepatic or renal insufficiency (Alanine Aminotransferase\u002FAspartate Aminotransferase\u002FCreatinine \\>3 times the upper limit of normal);\n* Anatomical abnormalities of the nasal cavity affecting intranasal drug administration;\n* Pregnant or breastfeeding women.","85 Years",{"count":516,"type":21},1800,[108],"The goal of this clinical trial is to learn if preoperative intranasal dexmedetomidine works to reduce perioperative myocardial injury and myocardial infarction in patients undergoing elective percutaneous coronary intervention (PCI). It will also learn about the safety of intranasal dexmedetomidine. The main questions it aims to answer are:\n\nDoes preoperative intranasal dexmedetomidine lower the incidence of perioperative myocardial injury and myocardial infarction after PCI? Does intranasal dexmedetomidine cause safety concerns in patients undergoing PCI? Researchers will compare intranasal dexmedetomidine to a placebo (a look-alike substance that contains no drug) to see if intranasal dexmedetomidine works to protect the heart during PCI.\n\nParticipants will:\n\nReceive either intranasal dexmedetomidine (100 μg) or a placebo (normal saline) 15 minutes before the PCI procedure Undergo blood tests to measure cardiac troponin levels before and after the procedure Be followed for up to 30 days after the procedure to record any heart-related events or side effects",[520,521,27,522],"Coronary Heart Disease","Myocardial Injury","Dexmedetomidine","2026-04-17",{"date":525,"type":34},"2026-04-24",{"date":527,"type":21},"2026-04",{"date":529,"type":21},"2028-04",{"name":531,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":533,"slug":4,"hasResults":11,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":226,"sex":539,"minAge":540,"maxAge":541,"enrollmentInfo":542,"targetDuration":544,"studyType":144,"phases":4,"briefSummary":545,"conditions":546,"keywords":547,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":41},"100287506","NCT03022552","Heart Attack Research Program: Platelet Sub-Study (HARP)","Heart Attack Research Program: Platelet Sub-Study (HARP); Platelet Collection for Patients With Myocardial Infarction","HARP","Inclusion Criteria:\n\n* Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms\n* Objective evidence of MI (either or both of the following):\n\n  * Elevation of troponin to above the laboratory upper limit of normal (ULN)\n  * ST segment elevation of ≥1mm on 2 contiguous ECG leads\n* Willing to provide informed consent and comply with all aspects of the protocol\n* Administration of aspirin at least 1 hour before cardiac catheterization\n* Administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization\n* Women and men with ≥50% of any major epicardial vessel on invasive angiography may participate\n\nExclusion Criteria:\n\n* Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month)\n* Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma\n* Pregnancy\n* Thrombolytic therapy for STEMI (qualifying event)\n* Use of any of the following medications:\n* Platelet antagonists (except aspirin and thienopyridines) within 7 days\n* NSAIDs (e.g., ibuprofen, naproxen) within 3 days.\n* Thrombocytopenia (platelet count \\\u003C100,000)\n* Thrombocytosis (platelet count \\>500,000)\n* Anemia (hemoglobin \\\u003C9 mg\u002Fdl)\n* Hemorrhagic diathesis","FEMALE","21 Years","99 Years",{"count":543,"type":21},350,"6 Months","This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Center, and participating external sites. May have concurrent enrollment with the HARP Main Imaging (NCT02914483). Additionally, a sex, group of age and race matched disease controls 'CATH-NOCA' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. Blood obtained during the initial catheterization and 2 months post-MI will be utilized for platelet testing.",[27],[27,548,549,550],"Platelets","Blood Collection","Genomics",{"date":91,"type":34},{"date":553,"type":34},"2020-07-01",{"date":555,"type":21},"2027-06-30",{"name":557,"class":40},"NYU Langone Health",{"id":559,"slug":4,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":566,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":41},"100561688","NCT06593418","Cardiac Radioablation for VT","A Phase I\u002FII Study of Cardiac Radioablation for Refractory Ventricular Tachycardia","Inclusion Criteria:\n\n* Participants must be 18 years or older.\n* Automatic implanted cardiac defibrillator present.\n* VT is monomorphic with at least two episodes of VT within an eight week (56 day) period as recorded by an AICD or heart failure related to VT or VT storm.\n* Ejection fraction ≥20%.\n* At least one previous cardiac ablation for VT.\n* VT refractory despite antiarrhythmic medications.\n* Likely to live for 12 months in the absence of VT.\n* AICD in a position in the chest RT to be given without direct radiation.\n* Woman of reproductive age must ensure that she won't become pregnant or breastfeed at the time of RT.\n* The participant has no contraindications to a Cardiac MRI as per routine Cardiology practice.\n\nExclusion Criteria:\n\n* Class IV heart failure\n* Abandoned leads.\n* Prior radiation therapy to the chest or upper abdomen.\n* Interstitial lung disease.",{"count":565,"type":21},24,[24],"The goal of this interventional study is to determine the minimum dose necessary for successful cardiac radioablation of refractory ventricular tachycardia (VT) and to study the utility of target volume definition using Delayed Enhancement Cardiac MRI (DE-CMR) .",[569,27],"Ventricular Tachycardia","2026-04-15",{"date":91,"type":34},{"date":573,"type":21},"2026-07",{"date":575,"type":21},"2028-01",{"name":577,"class":40},"Corewell Health East",{"id":579,"slug":4,"hasResults":11,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":226,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":22,"phases":587,"briefSummary":588,"conditions":589,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":506},"100536957","NCT06271577","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II","Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II (STLEUISII)","STLEUISII","Inclusion Criteria:\n\n* Male or female \\> 18 years of age.\n* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.\n* Symptoms of chest pain upon presentation at the Emergency Department of the participating institution.\n\nExclusion Criteria:\n\n* Inability or refusal of the patient and\u002For the patient's legally acceptable representative to provide written informed consent for any reason.\n* Other conditions that in the opinion of the Lead Investigator may increase risk to the subject and\u002For compromise the quality of the clinical trial.",{"count":586,"type":21},1000,[24],"AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).\n\nRecently, AliveCor developed a new device: AliveCor (AC) 12-lead (12L) ECG System to record simultaneously 4 leads of ECG and then generate complete 12-lead ECGs. A previous protocol at the University of Oklahoma involved 200 subjects with early prototypes of the AC 12L device with the specific aim to validate that it accurately generated 12-lead ECGs as compared to simultaneously acquired FDA-cleared 12-lead ECGs. The prototype version of the AliveCor 12L ECG System simultaneously measured four channels of ECG (leads I, II, V2, V4), calculated the remaining limb leads as is standard for 12-lead ECGs (Leads III, aVR, aVL, aVF) and synthesized the remaining 4 precordial ECG leads (V1, V3, V5, V6). This protocol will serve to validate the production version of the system against standard 12-Lead ECGs for the diagnosis of STEMI and NSTEMI in patients admitted to the Emergency Department or directly to the Cardiac Cath Lab for the evaluation of chest pain. It is anticipated that the waveforms for each of the 12 leads from the AC 12L ECG System will be highly correlated with the corresponding leads from the comparator commercially available 12-lead ECG devices used at participating sites. The purpose of this study is to clinically validate that the four-channel AC 12L ECG device can enable the diagnosis of STEMI and NSTEMI in a non-inferior manner to existing 12-lead ECG devices.",[27,590,591,592,593,594,595,86],"Ischemia","Myocardial Ischemia","Heart Diseases","Cardiovascular Diseases","Vascular Diseases","Heart Attack","2026-04-08",{"date":598,"type":34},"2026-04-09",{"date":600,"type":34},"2024-03-12",{"date":602,"type":21},"2027-03",{"name":604,"class":72},"AliveCor",{"id":606,"slug":4,"hasResults":11,"nctId":607,"briefTitle":608,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":22,"phases":612,"briefSummary":613,"conditions":614,"keywords":616,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":625,"leadSponsor":627,"locationsCount":41},"100633500","NCT07527494","Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction","TWIN-SCD STEMI","Inclusion Criteria:\n\n* History of ST-segment elevation myocardial infarction (STEMI) in the last 6 months\n* Signed informed consent\n* Affiliated to or beneficiary of a health insurance\n\nExclusion Criteria:\n\n* Renal failure (Creatinine clearance \\\u003C30 mL\u002Fmin), or a systemic illness likely to limit survival to \\\u003C1 year\n* Women who are pregnant, lactating, or who are planning to become pregnant within 2 years following her inclusion\n* Unable to understand the nature, risks, significance and implications of the clinical investigation or unwilling to provide written informed consent\n* Participant under legal protection",{"count":586,"type":21},[24],"TWIN-SCD STEMI is a multicentric prospective, non-randomized pilot study designed to establish a multiparametric model for predicting life-threatening ventricular arrhythmias in patients experiencing their first myocardial infarction. The primary objective of the study is to develop an algorithm with superior predictive performance (sensitivity and specificity) compared to the currently used criterion for the implantation of a cardiac defibrillator, which is a left ventricular ejection fraction (LVEF) of less than 35%.",[615,27],"Sudden Cardiac Death",[617,329,618,619,620],"Sudden cardiac death","Prediction","Multiparametric model","Ventricular Arrhythmia","2026-04-07",{"date":623,"type":34},"2026-04-14",{"date":570,"type":21},{"date":626,"type":21},"2034-12-31",{"name":628,"class":40},"University Hospital, Bordeaux",{"id":630,"slug":4,"hasResults":11,"nctId":631,"briefTitle":632,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":22,"phases":637,"briefSummary":638,"conditions":639,"keywords":640,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":648,"locationsCount":650},"100490398","NCT05665608","Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation","PROFID EHRA","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Naïve to implantation of any pacemaker or defibrillator\n3. Documented history of MI either as ST segment elevation myocardial infarction (STEMI) or as non-ST segment elevation myocardial infarction (NSTEMI) at least 3 months prior to enrolment.\n4. Symptomatic heart failure with New York Heart Association (NYHA) class II or III.\n5. On OMT for at least 3 months prior to enrolment.\n6. LVEF ≤ 35% (at transthoracic echocardiography or cardiac magnetic resonance imaging \\[MRI\\] at least 3 months after MI).\n7. Signed informed consent.\n\nInclusion criterion I3 defines myocardial infarction according to the 2018 ESC\u002FACC\u002FAHA\u002FWHF Fourth Universal Definition of myocardial infarction\n\nExclusion Criteria:\n\n1. Class I or IIa indication for implantation of an ICD for secondary prevention of SCD and ventricular tachycardia.\n2. Ventricular tachycardia induced in an electrophysiologic study.\n3. Unexplained syncope when ventricular arrhythmia is suspected as the cause of syncope.\n4. Class I or IIa indication for Cardiac Resynchronization Therapy (CRT)\n5. Foreseable violation of instruction for use (IFU) of the ICD device selected for implantation (valid for control group patients, only).\n6. Acute coronary syndrome or coronary angioplasty or coronary artery bypass grafting performed within 6 weeks prior to enrolment.\n7. Cardiac valve surgery or percutaneous cardiac valvular intervention performed within 6 weeks prior to enrolment.\n8. On the waiting list for heart transplantation.\n\n   Class I or IIa indication for implantation of an ICD for secondary prevention of SCD and ventricular tachy-cardia has to be assessed according to the 2022 ESC Guidelines for the management of patients with ven-tricular arrhythmias and the prevention of SCD.\n9. Any known disease that limits life expectancy to less than 1 year.\n10. Participation in another randomised clinical trial if study-specific treatment is still active at enrolment into PROFID EHRA.\n11. Previous participation in PROFID EHRA.\n\nParallel participation in sub-studies connected to this trial is permitted as well as in purely observational studies without any pre-defined intervention.",{"count":636,"type":21},3595,[24],"Patients who have survived a myocardial infarction (MI) are at increased risk for sudden cardiac death (SCD) caused by ventricular tachycardia and ventricular fibrillation. A severely reduced left ventricular ejection fraction (LVEF) as a rough overall measure of impaired heart function after MI was shown to indicate a higher risk for SCD. Based on this observation, two landmark randomised trials, MADIT II and SCD-HeFT, were conducted between end of the 1990s and early 2000s. These trials compared the survival of patients with severely reduced LVEF who received an implantable cardioverter-defibrillator with the survival of patients being on medical therapy alone. They reported a significantly better survival of patients in the defibrillator arm and led to international guideline recommendations for routine implantation of defibrillators in survivors of MI with severely impaired LVEF as a means for primary prevention of SCD. Since then, the management of these patients has changed dramatically with the advent of a series of novel drug classes that reduce not only mortality but specifically SCD leading to a substantial decrease of the sudden death rates as well as of the rates of appropriate defibrillator therapies implanted for primary prevention of SCD. At the same time, the complication rates associated with the defibrilllator therapy remain significant without obvious decrease. Thus, the risk-benefit of routine defibrillator implantation for primary prevention of SCD in patients with severely reduced LVEF has substantially changed since the conduction of the landmark trials that established this therapy. Due to the inherent risks and considerable costs of the defibrillator, a novel randomised adequately powered assessment of the potential benefit or harm of the defibrillator in survivors of MI with reduced LVEF under contemporary optimal medical treatment (OMT) appears imperative.\n\nOBJECTIVE:\n\nTo demonstrate that in post-MI patients with symptomatic heart failure who receive OMT for this condition, and with reduced LVEF ≤ 35%, OMT without ICD implantation (index group) is not inferior to OMT with ICD implantation (control group) with respect to all-cause mortality.",[615,27],[641,615,27],"Implantable Cardioverter Defibrillator","2026-03-31",{"date":644,"type":34},"2026-04-01",{"date":646,"type":34},"2023-11-16",{"date":419,"type":21},{"name":649,"class":40},"Charite University, Berlin, Germany",86,{"id":652,"slug":4,"hasResults":11,"nctId":653,"briefTitle":654,"officialTitle":654,"acronym":655,"eligibilityCriteria":656,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":22,"phases":659,"briefSummary":660,"conditions":661,"keywords":663,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":41},"100452204","NCT05168462","Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction","NORSHOCK","Inclusion criteria:\n\n1. Acute myocardial infarction, STEMI or NSTEMI\n2. Early revascularization by PCI\n3. Cardiogenic shock, characterized by:\n\nI. a. Systolic blood pressure (SBP) ≤ 90 mmHg for \\> 30 minutes, OR b. Use of drugs to maintain SBP \\> 90 mmHg at randomization.\n\nII. Clinical signs of impaired organ perfusion with at least one of the following criteria:\n\n1. Altered mental status\n2. Cold, clammy skin and extremities\n3. Oliguria with urine output \\\u003C 30ml\u002Fhour\n4. Serum lactate \\> 2.0 mmol\u002FL\n\nIII. Clinical signs of pulmonary congestion\n\nExclusion Criteria:\n\n1. Resuscitation \\> 30 minutes\n2. Mechanical cause of cardiogenic shock (e.g. papillary muscle rupture, ventricular septal rupture)\n3. Onset of shock \\> 12 hours\n4. Imminent need for mechanical circulatory support (i.e. ECPR)\n5. Women \\\u003C45 years",{"count":658,"type":21},776,[108],"Rationale: Pump failure due to acute myocardial infarction (AMI) can lead to cardiogenic shock (CS): a state of low blood flow to end-organs with subsequent multi-organ failure that is associated with high mortality rated. The first line pharmacologic treatment strategy in CS is noradrenaline. This vasopressor drug is used to maintain adequate blood pressures. The assumption is that a mean arterial blood pressure (MAP) ≥ 65 mmHg will improve flow and thereby tissue perfusion of myocardium and other tissues (e.g. renal). However, there is no evidence that an increase in MAP, if achieved by noradrenaline, leads to greater end-organ blood flow and better outcomes.\n\nObjective: With this study the investigators aim to investigate the (cost-)effectiveness of reduced noradrenaline in patients with CS by using a lower MAP target of ≥ 55 mmHg, compared to ≥ 65 mmHg. The investigators hypothesize that reduced use of noradrenaline will improve overall survival and decrease renal failure requiring renal replacement therapy.\n\nStudy design: Open label, randomized controlled multicenter trial\n\nStudy population: Adults patients with CS due to AMI\n\nIntervention: Treatment strategy of reduced noradrenaline, by using a lower MAP target ( ≥ 55 mmHg).\n\nMain study endpoint: composite of all-cause mortality and severe renal failure leading to renal replacement therapy within 30-days after randomization.",[662,27],"Cardiogenic Shock",[664,665,666,329],"Noradrenaline","Blood pressure target","Cardiogenic shock","2026-03-24",{"date":669,"type":34},"2026-03-27",{"date":671,"type":34},"2022-10-01",{"date":673,"type":21},"2028-04-01",{"name":675,"class":40},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",""]